pentoxifylline tablet, extended release
ncs healthcare of ky, llc dba vangard labs - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
aphena pharma solutions - tennessee, llc - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets, usp are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
ratio-pentoxifylline tablet (extended-release)
ratiopharm inc division of teva canada limited - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
nu-pentoxifylline-sr 400 mg tablet (extended-release)
nu-pharm inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
pentoxifylline tablet, extended release
bryant ranch prepack - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
ani pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
dyna-pentoxifylline sr 400 mg
pharma dynamics (pty) ltd - pentoxifylline - tablets - each slow release tablet contains pentoxifylline 400,0 mg
pentoxifylline 0.5% / triamcinolone acetonide 0.1% gel
sincerus florida, llc - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu), triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) -
pentoxifylline powder
ax pharmaceutical corp - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) -
trental 400 pentoxifylline (oxpentifylline) 400 mg modified release tablet blister pack
clinect pty ltd - pentoxifylline, quantity: 400 mg - tablet, modified release - excipient ingredients: povidone; hyetellose; titanium dioxide; hypromellose; erythrosine; purified talc; macrogol 8000; magnesium stearate - treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. trental 400 can thus improve function and symptoms but is not intended to replace more definitive therapy, such as vascular surgery, or removal of arterial obstructions when treating peripheral vascular disease.